US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback